Hellström V

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.

Carneiro A, Hahn A, Ellmark P, ..., Yachnin J, Ullenhag GJ

J Immunother Cancer 13 (1) - [2025-01-22; online 2025-01-22]

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus S, Hellström V, Wenthe J, ..., Loskog A, Ullenhag GJ

Cancer Gene Ther. 28 (10-11) 1188-1197 [2021-11-00; online 2020-12-14]